Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Neurosurgery, The Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, China.
Front Endocrinol (Lausanne). 2022 May 6;13:879702. doi: 10.3389/fendo.2022.879702. eCollection 2022.
Transsphenoidal surgery (TSS) is first-line treatment for giant pituitary adenomas (PAs). Although PA is a benign neuroendocrine tumor that originates from adenohypophysial cells, the surgical outcomes and prognosis of giant PAs differ significantly due to multiple factors such as tumor morphology, invasion site, pathological characteristics and so on. The aim of this study was to evaluate surgical outcomes of giant PAs in a single-center cohort.
The clinical features and outcomes of 239 patients with giant PA who underwent sphenoidal surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine from January 2015 to October 2021 were collected from medical records. The basic clinical information (age, gender, function etc.), surgical procedure, imaging features (maximum diameter, invasion characteristics, tumor shape etc.) and histopathological characteristics (pathological results, Ki-67, P53 etc.) were retrospectively reviewed. SPSS 25.0 and Stata 12.0 software were used for statistical analysis.
A total of 239 patients with giant PAs underwent TSS, of which 168 surgeries (70.29%) were endoscopic endonasal transsphenoidal (EETS) and 71 (29.71%) were microscopic transsphenoidal (MTS). The mean preoperative maximum diameter in the cohort was 45.64 mm. Gross-total resection was achieved in 46 patients (19.25%), near-total in 56 (23.43%), subtotal in 68 (28.45%), and partial in 69 (28.87%) patients. The maximum tumor diameter and Knosp grade were the significant factors that limited the extent of the resection of giant PAs. A total of 193 patients (80.75%) experienced surgical complications, and the most common complications were postoperative diabetes insipidus (DI) (91, 38.08%), intracranial infection (36, 15.06%) and cerebrospinal fluid (CSF) leaks (37, 15.48%). In addition, there was a significant difference in the incidence of CSF leaks between the neuroendoscopy group and the microscopic group (P < 0.05).
The management of giant PAs remains a therapeutic challenge due to their large size and postoperative complications. The maximum diameter and Knosp grade of giant PAs significantly limited the extent of resection, which warrants a reasonable surgical plan.
经蝶窦手术(TSS)是治疗巨大垂体腺瘤(PA)的首选方法。尽管 PA 是一种起源于腺垂体细胞的良性神经内分泌肿瘤,但由于肿瘤形态、侵袭部位、病理特征等多种因素的影响,其手术结果和预后存在显著差异。本研究旨在评估单中心队列中巨大 PA 的手术结果。
收集 2015 年 1 月至 2021 年 10 月在浙江大学医学院第二附属医院接受蝶窦手术的 239 例巨大 PA 患者的临床特征和结果,记录基本临床信息(年龄、性别、功能等)、手术过程、影像学特征(最大直径、侵袭特征、肿瘤形态等)和组织病理学特征(病理结果、Ki-67、P53 等)。采用 SPSS 25.0 和 Stata 12.0 软件进行统计学分析。
共有 239 例巨大 PA 患者接受了 TSS,其中 168 例(70.29%)为内镜经鼻蝶窦(EETS)手术,71 例(29.71%)为显微镜经蝶窦(MTS)手术。该队列的术前最大直径平均值为 45.64mm。46 例(19.25%)患者达到大体全切除,56 例(23.43%)为近全切除,68 例(28.45%)为次全切除,69 例(28.87%)为部分切除。最大肿瘤直径和 Knosp 分级是限制巨大 PA 切除程度的显著因素。共有 193 例(80.75%)患者发生手术并发症,最常见的并发症是术后尿崩症(DI)(91 例,38.08%)、颅内感染(36 例,15.06%)和脑脊液(CSF)漏(37 例,15.48%)。此外,神经内镜组与显微镜组 CSF 漏的发生率有显著差异(P<0.05)。
由于巨大 PA 体积大且术后并发症多,其治疗仍然具有挑战性。巨大 PA 的最大直径和 Knosp 分级显著限制了切除范围,需要制定合理的手术计划。